SHR-1210

Phase 2Completed

0 watching 0 views this week⚡ Active

Hype Score

Development Stage

✓

Pre-clinical

✓

Phase 1

Phase 2

Phase 3

Approved

Indication / Disease

Hepatocellular Carcinoma Non-Resectable

Conditions

Hepatocellular Carcinoma Non-Resectable

Trial Timeline

Nov 15, 2016 → Mar 3, 2020

NCT ID

NCT02989922

About SHR-1210

SHR-1210 is a phase 2 stage product being developed by Jiangsu Hengrui Medicine for Hepatocellular Carcinoma Non-Resectable. The current trial status is completed. This product is registered under clinical trial identifier NCT02989922. Target conditions include Hepatocellular Carcinoma Non-Resectable.

Hype Score Breakdown

Clinical

Activity

Company

Novelty

Community

Clinical Trials (9)

NCT ID	Phase	Status	Start	Completion	Indication
NCT03558191	Phase 2	Completed	Aug 14, 2018	Dec 30, 2021	Nasopharyngeal Carcinoma
NCT03557411	Phase 2	UNKNOWN	Jul 9, 2018	Jul 9, 2020	Non-Small-Cell Lung Cancer
NCT03363555	Phase 2	UNKNOWN	May 29, 2018	Jun 1, 2021	Extranodal NK/T-cell Lymphoma, Nasal Type
NCT03222440	Pre-clinical	Completed	Jul 19, 2017	Nov 1, 2019	Esophageal Cancer
NCT03155425	Phase 2	Completed	Jun 9, 2017	Sep 30, 2020	Hodgkin Lymphoma, Adult
NCT03085069	Phase 2	UNKNOWN	May 3, 2017	Aug 20, 2023	Lung Neoplasms
NCT02989922	Phase 2	Completed	Nov 15, 2016	Mar 3, 2020	Hepatocellular Carcinoma Non-Resectable
NCT02738489	Phase 1	Completed	Apr 13, 2016	Jan 8, 2020	Advanced Melanoma
NCT02721589	Phase 1	Completed	Apr 6, 2016	Nov 17, 2019	Advanced Solid Tumors

Competing Products

20 competing products in Hepatocellular Carcinoma Non-Resectable

See all competitors

Product	Company	Stage	Hype Score
CT-01 + EVEROLIMUS	Captor Therapeutics	Phase 1	25
ateganosine + Cadonilimab	MAIA Biotechnology	Phase 1	25
Ramucirumab + Placebo	Eli Lilly	Phase 3	77
ERY974 + Tocilicumab + Atezolizumab + Bevacizumab	Chugai Pharmaceutical	Phase 1	33
Atezolizumab + Bevacizumab + Tiragolumab	Chugai Pharmaceutical	Phase 3	77
GC33(RO5137382) + Sorafenib	Chugai Pharmaceutical	Phase 1	33
CS-1008 2 mg/kg + Sorafenib + CS-1008 6/2 mg/kg + CS-1008 6/6 mg/kg + CS-1008 4 mg/kg + CS-1008 6 mg/kg	Daiichi Sankyo	Phase 2	52
Tivantinib + Placebo	Daiichi Sankyo	Phase 3	77
OSI-906 + Placebo	Astellas Pharma	Phase 2	52
Enzalutamide + Placebo	Astellas Pharma	Phase 2	52
Enzalutamide + Enzalutamide with Sorafenib	Astellas Pharma	Phase 1	33
Recombinant oncolytic virus M1, anti PD-1 antibody, Apatinib	Sun Pharmaceutical	Phase 1	33
Irinotecan + Sonidegib + Sorafenib	Sun Pharmaceutical	Phase 2	52
mFOLFOX7 combined with Camrelizumab and apatinib	Sun Pharmaceutical	Phase 2	52
camrelizumab& apatinib	Sun Pharmaceutical	Phase 2	52
Lenvatinib	Eisai	Pre-clinical	23
Lenvatinib Pill	Eisai	Phase 2	52
Sorafenib + Sorafenib	Eisai	Phase 1/2	41
Lenvatinib	Eisai	Phase 2	52
Lenvatinib + Nivolumab	Eisai	Phase 2	52

Other Products from Jiangsu Hengrui Medicine

ApatinibApproved

Remimazolam TosilateApproved

Henagliflozin 10 mg daily + Metformin 1700 mg dailyApproved

ImrecoxibApproved

IvarmacitinibApproved